Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Saved in:
| Title: | Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. |
|---|---|
| Authors: | Gallo S; Pfizer Deutschland GmbH, Berlin, Germany., Charbonnel B; University of Nantes, Nantes, France., Goldman A; Pfizer Inc., Collegeville, Pennsylvania., Shi H; Pfizer Inc., New York, New York., Huyck S; Merck & Co., Inc., Kenilworth, New Jersey., Darekar A; Pfizer Ltd., Tadworth, UK., Lauring B; Merck & Co., Inc., Kenilworth, New Jersey., Terra SG; Pfizer Inc., Andover, Massachusetts. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Apr; Vol. 21 (4), pp. 1027-1036. Date of Electronic Publication: 2019 Feb 14. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
